Company intelligence / Profile preview
PrimeVax Immuno-Oncology
Orange, California, United Statesprimevax.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
PV001-DV has been tested in 21 healthy volunteers, demonstrating safety and powerful immune stimulation. Strong anti-tumor mechanisms have been repeatedly demonstrated in laboratory settings, with matching immune stimulation across healthy humans and cancer patient blood samples[1].
- Therapeutic areas
- OtherOncology
- Modalities
- Oncolytic virotherapyDendritic cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
U.S. Army (exclusive license for DENV-1 45AZ5)
Beyond the preview
Go deeper on PrimeVax Immuno-Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PrimeVax Immuno-Oncology.